Introduction {#sec1-1}
============

Recently, in addition to the function of vitamin D on calcium metabolism, bone, proliferation, differentiation, and immune modulation, few evidence indicates that vitamin D plays an important role in the brain, nervous system health, and depression.\[[@ref1]\] Both vitamin D deficiency and insufficiency show global burden\[[@ref2]\] that is more prevalent in women.\[[@ref3]\]

The anxiety disorders include some of the most common and disabling psychiatric illnesses. Anxiety is characterized by excessive and persistent worry that can reduce the ability to perform normal activities in life.\[[@ref4]\]

A systematic review and meta-analysis has indicated that diabetes is related to increased risk of anxiety disorders.\[[@ref5]\] Uncontrolled blood sugar is associated with anxiety and the rates of generalized anxiety disorder (GAD) is higher in diabetes.\[[@ref6]\]

Tumor necrosis factor-alpha (TNF-α) and C-reactive protein (CRP) are increased in anxiety due to inflammation and psychoneuroimmunologic pathways.\[[@ref7]\] Anxiety can weaken the immune system\[[@ref8]\] while some studies show that diabetic patients have higher levels of inflammatory markers such as CRP, interleukin-1 (IL-1), IL-6, TNF-α, interstitial cellular adhesion molecule-1, and vascular cellular adhesion molecule-1.\[[@ref9]\] On the other hand, evidence suggests that both depression and anxiety stimulate inflammation in diabetic patient.\[[@ref10]\]

Previous interventions have shown the impact of vitamin D deficiency on depression,\[[@ref11]\] however, limited studies have been carried out to illustrate the association of anxiety disorders with serum levels of vitamin D.\[[@ref12]\] Penckofer *et al*. reported 6-month intervention with 50,000 IU vitamin D significantly decreased depression and anxiety in type 2 diabetes mellitus (T2DM) who had depression.\[[@ref13]\] Supplementation with vitamin D reduced anxiety levels in premenstrual syndrome in adolescents who had severe vitamin D deficiency.\[[@ref14]\] At present, there have been no studies regarding the effect of vitamin D supplementation in women with T2DM affected by anxiety. Therefore, the main aim of this study was to examine the potential impact of vitamin D on anxiety in diabetic women with vitamin D deficiency.

Methods {#sec1-2}
=======

Participants {#sec2-1}
------------

In the present randomized double-blind placebo-controlled clinical trial, 64 women with T2DM were recruited from Shahr-e-Kord Diabetes Clinic, Iran. The participants were T2DM women between 20 to 60 years old diagnosed with mild, moderate, or severe anxiety. All participants had vitamin D deficiency or insufficiency \[10 (ng/mL) ≤ serum vitamin D ≤30 (ng/mL)\]. Diagnosis of T2DM was on the bases of the World Health Organization guidelines.\[[@ref15]\]

Anxiety was determined by the Depression, Anxiety and Stress Scales (DASS- 21) questionnaire apply for clinical and non-clinical populations that had previously been validated in Iranian population.\[[@ref16]\] Each question of DASS-21 has four scales (0 = did not apply to me at all, 1 = applied to me to some degree or some of the time, 2 = applied to me to a considerable degree or a good part of the time, and 3 = applied to me very much or most of the time) to determine the symptoms of anxiety and depression. The sum of scores for each subscale should be multiplied to 2 to evaluate original depression anxiety stress scale of 42 items. Patient\'s scores on DASS-21 scale can run between 0 to 42. Cut-off points for anxiety score are 0--7, 8--9, 10--14, 15--19, and more than 20 to classify patients into normal, mild, moderate, severe, and extremely severe state of anxiety, respectively.\[[@ref17][@ref18]\]

General characteristics of the participants including age, educational levels, suffering from other diseases, duration of T2DM, and medication history were collected through face-to-face interview pre-intervention.

Patients that had neurological or psychiatric disorders, took any medications for depression or vitamin D/multivitamin supplements during the last 4 month, consumed alcohol, were pregnant, or lactating were excluded. The purpose of the study was explained for eligible participants. Women who had the aforementioned criteria and agreed to participate in the study completed informed consent form before commencing the intervention.

Study design, randomization, and blindness {#sec2-2}
------------------------------------------

Current study was a randomized double-blind placebo-controlled clinical trial. Block randomization (with block sizes of two) was performed using the Random Allocation Software: (RAS). Participants were randomly allocated into either intervention or placebo group \[[Figure 1](#F1){ref-type="fig"}\]. The intervention and placebo groups received 50,000 IU cholecalciferol and paraffin soft gel capsules, respectively, fortnightly for 16 weeks. Since normal upper limit of vitamin D intake is 10,000 IU/day, the recommended dosage was regarded safe.\[[@ref19]\]

![Algorithm of study participants in the two groups](IJPVM-10-17-g001){#F1}

All participants and investigators including the laboratory staff were blind to randomization. Placebo was similar to vitamin D soft gels in color and size and they were presented in dark bottles (A, B) coded by a subject who was not involved in any procedures of the study. Both supplements were produced by Zahravi Pharm Co; Tabriz, Iran.

Sun exposure time {#sec2-3}
-----------------

At the beginning and end of the study, sun exposure rate of participants were assessed through a validated questionnaire. Duration of exposure to sunlight \[the average minutes (min)/hours (h) of a usual day in the previous week\] was asked using a questionnaire.\[[@ref20]\] The duration of sun exposure was classified as 0--10 min; 10 min--1 h; 1--2 h; and \>2 h. Furthermore, the time of exposure to sunlight during a day was also asked and classified as follows: 7 am--10 am; 10 am--3 pm; and 3 pm--5 pm. At the end of the questionnaire, the part of the body that was exposed to sunlight was asked from all participants. Because of the intense sunlight, the highest score was the exposure of sunlight at 10--3 o'clock.\[[@ref21]\]

Dietary assessment {#sec2-4}
------------------

Dietary intakes were assessed by a single researcher using a valid 3-day food record (2 working days and 1 weekend) at pre- and post-intervention. Nutritionist IV software program (First Databank Inc., Hearst Corp., San Bruno, CA, USA) modified for Iranian food was used for dietary analysis.

Physical activity assessment {#sec2-5}
----------------------------

The physical activity level of participants was determined using the short version of International Physical Activity Questionnaire (IPAQ) validated for Iranians.\[[@ref22]\] at pre- and post-intervention.

Anthropometric indices assessment {#sec2-6}
---------------------------------

Anthropometric indices such as height (by a graded wall to the nearest of 0.1 cm), weight (fasting weight was measured with the accuracy of 0.1 kg using Seca scales), waist circumferences (WC) was measured at the midway between lower rib and iliac crest, and hip circumferences (HC) was recorded using standard methods\[[@ref23]\] at the baseline and post-intervention by a trained nutritionist. Body mass index (BMI) was calculated by dividing weight (kg) to square height (m^2^).

Sample size determination {#sec2-7}
-------------------------

Considering 0.05 as type 1 error and 0.2 as type 2 error (power = 80%) based on previous study and using standard deviation equal to 1 and change in mean equal to 0.81 of high sensitivity CRP (hs-CRP), 24 subjects were needed in each group. We added 10% to sample size because of covering possible dropouts to reach 25 participants in each group.\[[@ref24]\]

Laboratory analyses {#sec2-8}
-------------------

A total of 10 ml of fasting blood samples were collected from each participant after 12 h fasting at the beginning and at the end of study. The blood samples were centrifuged to separate serums and they were then stored at −80°C until further analysis. Serum 25-hydroxy vitamin D levels were quantitatively measured using the enzyme-linked immunosorbent assay (ELISA) method (Monobind ELISA kit, USA). Serum hs-CRP concentrations were assayed using ELISA kit (Diagnostics Biochem Canada Inc, Ontario, Canada).

Statistical analysis {#sec2-9}
--------------------

We analyzed data using the SPSS software, version 17 (SPSS Inc, Chicago, IL). The Shapiro--Wilk test was performed to evaluate the normality of the distributions. The between-group comparisons for baseline characteristics were done using independent *t*-test or Mann--Whitney U test for variables with normal and non-normal distribution, respectively. Wilcoxon test and paired *t* tests were applied for within-group analysis. We used analysis of covariance (ANCOVA) test adjusted for baseline values and confounders such as fat and vitamin C intake to compare the two groups pre- and post-intervention. *P*-values \<0.05 were considered statistically significant. Between- and within-group analyses of subgroups were performed with the similar methods used previously.

Ethical consideration {#sec2-10}
---------------------

The present study was carried out in accordance with the guidelines described in the Declaration of Helsinki.\[[@ref25]\] It was approved by the Medical Ethics Committee of Isfahan University of Medical Sciences (Reg. No: IR. MUI. REC.1395.3736). This study has been registered in the Iranian registry of clinical trials (<http://www.irct.ir>) under the number IRCT20170927036451N1.

Results {#sec1-3}
=======

Sixty-four TDM2 women with mean ± SD age of 47.43 ± 9.57 years were included to our study. Finally, 51 participants (26 patients in the vitamin D and 25 patients in the placebo groups) completed the trial \[[Figure 1](#F1){ref-type="fig"}\]. Demographic information including education, BMI, physical activity, sun exposure, waist-to-hip ratio, and serum 25-hydroxy vitamin D at the beginning and post-intervention showed no significant differences \[[Table 1](#T1){ref-type="table"}\]. Compliance rate of taking soft pearls was \>90% in the two groups.

###### 

Baseline characteristic of participants in the study groups

  Variables                            Supplement group (*n*=26)   Placebo group (*n*=25)   *P*
  ------------------------------------ --------------------------- ------------------------ ---------
  Age (year)                           48.5±7.58^a^                46.32±11.16^a^           0.42^†^
  FBS (mg/dL)                          166.63±63.63                158.32±54.14             0.38^†^
  Education, *n* (%)                                                                        
   Primary/high school                 18 (69.40)                  13 (52.00)               0.42\*
   Diploma                             4 (15.30)                   7 (28.00)                
   University degree                   4 (15.3)                    5 (20.00)                
  Exposure to sunlight score           31.02±24.67^a^              32.54±6.71^a^            0.85^†^
   BMI (kg/m^2^)                       30.21±4.42^a^               29.19±6.41^a^            0.16^†^
   Waist-to-hip ratio                  0.94±0.05                   0.91±0.10                
  Physical activity (MET/hours\*day)   31.48±18.12^a^              30.21±33.05^a^           0.09^†^
  Use of sunscreen cream, *n* (%)                                                           
   Never                               14 (53.84)                  14 (56.00)               0.92^†^
   Sometimes                           7 (26.92)                   5 (20.00)                
   Very often                          3 (11.54)                   3 (12.00)                
   Always                              2 (7.70)                    3 (12.00)                
  25-hydroxy vitamin D (ng/mL)         21.32±5.85^a^               20.73±6.47^a^            0.37^†^

^†^By independent *t*-test, \*By Chi-square test, ^a^Mean±SD. SD=Standard deviation, FBS=Fasting blood sugar, BMI=Body mass index, MET=Metabolic equivalent of task

Analysis of 3-day food records showed no significant differences in terms of nutrients and energy intake, except for fat (*P* = 0.02) and vitamin C (*P* = 0.02) at the baseline \[[Table 2](#T2){ref-type="table"}\].

###### 

Comparison of dietary intake, anthropometric indices, and physical activity in the study groups pre- and post-intervention

  Variables                                    Supplement group (*n*=26)   Placebo group (*n*=25)   *P*^†^
  -------------------------------------------- --------------------------- ------------------------ ----------
  Weight (kg)                                                                                       
   Baseline                                    74.55±12.20                 74.40±16.10              0.97^†^
   16 weeks                                    75.13±12.29                 75.76±16.33              0.88^†^
   *P*\*^,‡^                                   0.64                        0.06                     
  Waist circumference (cm)                                                                          
   Baseline                                    100.87±15.02                99.36±14.62              0.71
   16 weeks                                    100.47±9.61                 99.52±13.54              0.87
   *P*^‡^                                      0.85                        0.92                     
  Waist-to-hip ratio                                                                                
   Baseline                                    0.94±0.05                   0.92±0.10                0.18
   16 weeks                                    0.95±0.56                   0.92±0.11                0.18
   *P*^‡^                                      0.02                        0.01                     
  BMI (kg/m^2^)                                                                                     
   Baseline                                    30.21±4.42                  29.20±6.41               0.16
   16 weeks                                    30.42±4.30                  29.73±6.48               0.21
   *P*^¥^                                      0.55                        0.08                     
  25(OH) D3 (ng/mL)                                                                                 
   Baseline                                    21.32±5.85                  20.73±6.47               0.81
   16 weeks                                    29.11±11.70                 22.4±11.36               0.04
   *P*^¥^                                      \<0.001\*\*                 0.89                     
  Energy intake (kCal/day)                                                                          
   Baseline                                    2337.92±410.20              2203.60±442.12           0.26
   16 weeks                                    2276.82±448.80              2084.20±257.66           0.07
   *P*^‡^                                      0.07                        0.24                     
  Carbohydrate intake (g/day)                                                                       
   Baseline                                    356.29±84.41                322.25±66.19             0.11
   16 weeks                                    343.28±73.36                311.16±56.25             0.86
   *P*^‡^                                      0.11                        0.44                     
  Protein intake (g/day)                                                                            
   Baseline                                    91.80±15.57                 86.99±15.07              0.33
   16 weeks                                    86.90±17.92                 100.48±9.61              0.44
   *P*^‡^                                      0.57                        0.98                     
  Fat intake (g/day)                                                                                
   Baseline                                    64.29±10.61                 56.25±11.51              0.02\*\*
   16 weeks                                    62.24±15.20                 53±13.93                 0.43^†^
   *P*^‡^                                      0.40                        0.54                     
  Vitamin C intake (mg/day)                                                                         
   Baseline                                    125.66±58.79                84.72±54.17              0.02\*\*
   16 weeks                                    101.81±51.50                88.43±49.50              0.38
   *P*^‡^                                      0.07                        0.68                     
  Vitamin D intake (mcg/day)                                                                        
   Baseline                                    0.84±1.28                   0.56±0.72                0.33
   16 weeks                                    1.06±1.23                   0.77±0.79                0.33
   *P*^¥^                                      0.48                        0.27                     
  Saturated fatty acids intake (g/day)                                                              
   Baseline                                    17.89±9.16                  16.11±11.24              0.27
   16 weeks                                    16.73±8.72                  12.67±6.23               0.07
   *P*^¥^                                      0.10                        0.33                     
  Monounsaturated fatty acids intake (g/day)                                                        
   Baseline                                    25.54±11.11                 21.41±7.06               0.12
   16 weeks                                    24.40±14.80                 19.84±6.91               0.18
   *P*^‡^                                      0.56                        0.28                     
  Polyunsaturated fatty acids intake (g/day)                                                        
   Baseline                                    19.93±5.51                  20.36±9.23               0.84
   16 weeks                                    18.27±4.21                  16.96±4.24               0.26
   *P*^‡^                                      0.04                        0.84                     
  Exposure to sunlight score                                                                        
   Baseline                                    31.02±24.67                 32.54±33.05              0.85
   16 weeks                                    40.29±35.23                 32.80±25.19              0.54
   *P*^‡^                                      0.44                        0.98                     
  Physical activity (MET/hours\*day)                                                                
   Baseline                                    31.48±18.12                 25.81±15.81              0.09
   16 weeks                                    30.28±16.99                 24.95±12.96              0.19
   *P*^¥^                                      0.50                        0.99                     

Variables are represented as mean±SD. ^†^By independent *t*-test, ^‡^By paired sample *t*-test, ^¥^By Wilcoxon signed rank test, \*Indicates between groups comparisons, \*\**P*\<0.05. SD=Standard deviation, BMI=Body mass index, MET=Metabolic equivalent of task

Anthropometric variables, sun exposure, and physical activity of both the groups did not change after intervention.

The mean ± SD of anxiety score at the beginning of the study in supplement group was 12.31 ± 4.26 which indicated moderate anxiety. At the end of intervention in vitamin D group, mean ± SD of anxiety severity was 9.15 ± 4.54 this average is classified as mild anxiety level.

Significant reduction in anxiety score was seen in vitamin D group vs. control group (*P* = 0.001), \[[Table 1](#T1){ref-type="table"}\].

Depression changes were not different significantly in vitamin D group vs. controls (*P* \> 0.05), while the depression score significantly decreased post-intervention in vitamin D group, that determined by within-group analyses \[[Table 3](#T3){ref-type="table"}\]; (*P* = 0.03).

###### 

Effects of vitamin D on inflammatory biomarkers, anxiety, stress, and depression

  Variables                Intervention group (*n*=26)   Placebo group (*n*=25)   *P*             *P*\*
  ------------------------ ----------------------------- ------------------------ --------------- -------------
  Anxiety                                                                                         
   Baseline                12.31±4.26                    10.44±5.05               0.16^†^         \<0.001\*\*
   16 weeks                9.15±4.54                     13.28±4.61               0.02^†,^\*\*    
   Change                  -3.15±4.65                    1.64±4.75                0.001^†,^\*\*   
   *P* (within group)^‡^   \<0.001\*\*                   0.10                                     
  Stress                                                                                          
   Baseline                13.27±5.38                    1.84±4.29                0.68^†^         0.42
   16 weeks                12.2±6.63                     13.28±4.61               0.51^†^         
   Change                  -1.04±4.68                    -0.56±2.80               0.66^†^         
   *P* (within group)^‡^   0.26                          0.33                                     
  Depression                                                                                      
   Baseline                11.88±4.84                    12.44±5.09               0.69^†^         0.29
   16 weeks                9.88±3.88                     11.08±5.28               0.36^†^         
   Change                  -2.00±4.38                    -1.36±4.07               0.59^†^         
   *P* (within group)^¥^   0.03\*\*                      0.11                                     
  hs-CRP (mg/L)                                                                                   
   Baseline                3.23 (1.37, 9.06)             4.12 (2.32, 10.65)       0.35^₤^         \<0.001\*\*
   16 weeks                2.39 (1.18, 7.93)             4.29 (2.56, 10.23)       0.05^₤^         
   Change                  -0.27 (-0.89, -0.22)          2.58 (-0.21, 1.21)       0.01^₤^         
   *P* (within group)^¥^   0.01\*\*                      0.16                                     
  IL-10 (ng/mL)                                                                                   
   Baseline                80.25 (61.75, 102.00)         93.00 (70.75, 115.00)    0.22^₤^         0.02\*\*
   16 weeks                93.00 (64.27, 157.27)         83.00 (66.90, 106.00)    0.44^₤^         
   Change                  8.80 (-2.86, 27.75)           2.1 (-11.00, 10.70)      0.04^₤^         
   *P* (within group)^¥^   0.02\*\*                      0.93                                     

Variables are represented mean±SD or median (25^th^, 75^th^ percentiles). \*By ANCOVA for between groups' comparisons (adjustment was made for baseline values, fat, and vitamin C intake), ^†^By Independent *t*-test, ^‡^By paired sample *t*-test, ^¥^Obtained from Wilcoxon signed rank test, ^₤^Obtained from Mann-Whitney test, \*\**P*\<0.05. SD=Standard deviation, hs-CRP=high sensitivity C-reactive protein, IL-10=interleukin 10

Patients were classified into two subgroups as 10\> serum vitamin D ≥20 and 20\> serum vitamin D ≥30. Subgroup analysis indicated that anxiety score decreased in supplement group in both categories of serum vitamin D (*P* \< 0.5). Depression score in supplement group with lower vitamin D levels was significantly reduced (*P* = 0.04). Stress did not change significantly in any of the groups and also in vitamin D subgroups \[[Table 4](#T4){ref-type="table"}\]. Reduction in hs-CRP levels was significant in patients who took vitamin D supplement in both categories (*P* = 0.01).

###### 

Comparison of the baseline and post-intervention values of variables based on serum vitamin D (ng/mL) status in the study groups

  Variables                10 \>Vitamin D ≥20      20 \>Vitamin D \>30                                                                    
  ------------------------ ----------------------- ----------------------- -------------- ----------------------- ----------------------- --------------
  Anxiety                                                                                                                                 
   Baseline                12.89±3.14              11.11±5.16              0.06^†^        12.00±4.82              11.12±5.51              0.63^†^
   16 weeks                9.78±3.68               10.78±4.04              0.06^†^        9.82±4.34               12.18±4.26              0.12^†^
   Change                  -5±4.92                 2.67±2.31               0.01^†,^\*\*   -2.18±3.33              1.06±2.73               0.03^†,^\*\*
   *P* (within group)^‡^   0.02                    0.24                                   0.05                    0.27                    
  Stress                                                                                                                                  
   Baseline                13.22±4.23              12.77±2.63              0.79^†^        13.29±6.02              14.44±4.98              0.33^†^
   16 weeks                7.88±3.89               11.89±3.69              0.96^†^        11.88±4.97              13.56±5.01              0.43^†^
   Change                  -0.33±3.33              -00±1.73                0.84^†^        0.25                    0.24                    0.70^†^
   *P* (within group)^‡^   0.83                    0.99                                   -1.42±3.91              -0.88±2.87              
  Depression                                                                                                                              
   Baseline                12.77±4.14              9.22±4.15               0.46^†^        11.40±5.22              13.18±5.06              0.33^†^
   16 weeks                12.89±6.27              12.78±4.02              0.68^†^        9.94±4.05               11.25±5.00              0.42^†^
   Change                  -3.00±2.71              -0.33±2.57              0.14^†^        -1.47±2.71              1.94±3.32               0.76^†^
   *P* (within group)^‡^   0.04                    0.78                                   0.22                    0.09                    
  hs-CRP (mg/L)                                                                                                                           
   Baseline                2.52 (1.19, 12.19)      2.79 (1.54, 4.27)       0.73^₤^        3.35 (1.80, 7.05)       7.18 (2.71, 12.31)      0.09^₤^
   16 weeks                2.21 (1.12, 9.09)       2.56 (1.84, 5.51)       0.07^₤^        2.56 (1.18, 7.88)       6.01 (3.02, 11.89)      0.04^₤^
   Change                  -0.75 (-1.82, -0.14)    0.35 (-0.39, 0.86)      0.01^₤,^\*\*   -0.21 (-0.86, 0.27)     0.23 (-1.51, 1.41)      0.08^₤^
   *P* (within group)^¥^   0.008\*\*               0.23                                   0.03                    0.26                    
  IL-10 (ng/mL)                                                                                                                           
   Baseline                68.00 (48.70, 111.20)   99.00 (59.30, 118.50)   0.34^₤^        85.00 (62.50, 107.00)   90.00 (74.12, 116.00)   0.48^₤^
   16 weeks                92.00 (48.80, 143.25)   83.00 (63.50, 114.50)   0.76^₤^        94.00 (81.25, 164.50)   83.50 (68.85, 109.25)   0.26^₤^
   Change                  4.40 (-6.35, 19.00)     00.00 (-10.40, 6.20)    0.34^₤^        10.00 (-3.25, 49.10)    2.55 (-20.75, 14.76)    0.08^₤^
   *P* (within group)^¥^   0.31                    0.67                                   0.67                    0.83                    

Variables are represented mean±SD or median (25^th^, 75^th^ percentiles). ^†^By independent *t*-test, ^‡^By paired sample *t*-test, ^¥^Obtained from Wilcoxon signed rank test, ^₤^Obtained from Mann-Whitney test, \*\**P*\<0.05. SD=Standard deviation, hs-CRP=high sensitivity C-reactive protein, IL-10=Interleukin 10

Discussion {#sec1-4}
==========

Our study showed that 16 weeks supplementation with 50,000 IU vitamin D decreased anxiety, hs-CRP and increased IL-10 concentrations in T2DM women with anxiety for a period of 4 months. Recently Penckofer *et al*. reported that vitamin D supplementation for 6 month can decrease depression and anxiety in diabetic patient with symptoms of depression.\[[@ref13]\] Several studies have shown that vitamin D deficiency is associated to poorer mental health.\[[@ref26][@ref27]\] However, overall effect of vitamin D in a meta-analysis reported no significant reduction in depression after supplementation. It is worthy to note that most studies examined the individuals with low depression and sufficient serum levels of vitamin D at the baseline.\[[@ref28]\]

Vitamin D supplementation reduced anxiety in this trial. Bičíková *et al*. showed that lower serum level of calcidiol was related to anxiety in patients with anxiety disorders assessed by Clinical Global Impressions Scale (CGI).\[[@ref29]\] Ataie-Jafari have indicated that anxiety, poor quality sleep, depression, and worry were related to vitamin D deficiency in Iranian adolescences.\[[@ref30]\] A trial by Dean *et al*. indicated that vitamin D has no therapeutic effects on anxiety and depression in healthy adult.\[[@ref31]\] A study carried out on the effect of daily supplementation with dosage of 5000 IU vitamin D in young adults did not show any changes in anxiety scores,\[[@ref31]\] however, another study reported that anxiety improved in diabetic patients received 50,000 IU vitamin D on weekly basis for 6 month.\[[@ref13]\]

Depression score did not change significantly, however, subgroup analysis in accordance to the baseline 25-hydroxy vitamin D indicated that depression scale decreased in group with lower levels of serum vitamin D. Although recent studies indicated serum 25(OH) vitamin D concentrations have inverse relation with symptoms of depression.\[[@ref32]\] Other studies have reported non-significant effect of vitamin D on depression in individuals with lower scores of depression,\[[@ref33][@ref34]\] justifying the challenge between subgroups analysis and overall result. Furthermore, vitamin D treatment for longer periods may exert therapeutic effect to ameliorate depression in patients with clinically proven depression.\[[@ref35]\] Future randomized controlled trials are needed to examine the effect of vitamin D on patients with vitamin D deficiency and depression.

In the present study, there was no improvement in patients' stress scale. Black *et al*. in a cross-sectional study did not find any relationships between stress and serum level of vitamin D assessed through DASS-21.\[[@ref12]\] Wang *et al*. reported that vitamin D could not reduce physiological distress in hospitalized patients with vitamin D and vitamin C deficiency.\[[@ref36]\]

We found that vitamin D supplementation for 4-month period decreased hs-CRP while increased IL-10 levels. Previous observational studies have revealed that diabetic patients have significantly higher hs-CRP concentrations than healthy people.\[[@ref37]\] Moreover, anxiety is associated with high serum levels of hs-CRP,\[[@ref38]\] while IL-10 level, as an anti-inflammatory biomarker, is low in patients with anxiety.\[[@ref7]\] Improving inflammatory markers in GAD could help reduce anxiety.\[[@ref39]\] It seems that anxiety disorders are associated with defective activity of hypothalamus-pituitary-adrenal axis (HPA), higher pro-inflammatory, and low anti-inflammatory cytokines.\[[@ref40][@ref41]\]

Diabetic patients are at higher risk of oxidative stress, heart disease, and anxiety disorder.\[[@ref42][@ref43]\] Vitamin D supplementation is effective for reducing serum hs-CRP concentrations,\[[@ref44]\] however, some authors did not report any changes in women with gestational diabetes.\[[@ref45]\] The difference in the results of studies could be due to supplementation dosage, treatment period, and the population studied. The higher serum concentration of hs-CRP at baseline is effective in result of vitamin D interventions.\[[@ref46]\] Supplementation with vitamin D for 35 days increased IL-10 in vitamin D insufficient subjects \[serum 25(OH) D \<29 ng/mL\].\[[@ref47]\] Furthermore, 3-month supplementation with 50,000 IU vitamin D increased IL-10 in multiple sclerosis patients.\[[@ref48]\] Subgroup analysis showed that the increase in IL-10 in both subgroups with vitamin D supplementation was non-significant and could be attributed to smaller sample size in subgroups.

Vitamin D supplement had no significant effects on BMI and anthropometric indices as previous studies also confirmed these results.\[[@ref49][@ref50][@ref51]\] A meta-analysis indicated that serum vitamin D has inverse relationship with fat mass, however, vitamin D supplementation was not effective on fat mass.\[[@ref52]\]

Recently, it has been reported vitamin D responsive factors such as vitamin D receptors (VDRs) and the regions of serotonin receptors and tryptophan hydroxylase, have relationship with depression.\[[@ref53]\] On the other hand, another study did not find any association between vitamin D levels, polymorphism of vitamin D receptor, and depression.\[[@ref54]\] In the future, more studies are needed to show the mediatory role of genes in vitamin D impact.

As a limitation of our study, we were unable to measure the seasonal changes that could affect the outcome. However, the intervention was not conducted in different seasons. The strength of our study was the continuous follow-up during the intervention.

Conclusions {#sec1-5}
===========

Vitamin D supplementation could improve anti-inflammatory biomarkers and reduce cardiovascular risk factor and anxiety in T2DM women with anxiety and vitamin D deficiency. More studies are warranted to clarify the beneficial effects of supplementation with vitamin D on male diabetes patients having anxiety.
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